A collaboration between IsoPlexis and Kite, a Gilead Company, resulted in the publication of clinical data in demonstrating a significant association between the functionality of anti-CD19 CAR-T cell product before treatment and the objective response in patients with non-Hodgkin lymphoma. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy before treatment, as well as to improve both pre-infusion product potency testing and guide cell product optimization. These findings have been published in Blood.
IsoPlexis partnered with Nektar Therapeutics in a collaboration focused on further defining the functional impact of NKTR-214 in the clinic, at the single-cell level, with the goal of revealing both mechanism and potential immune correlates with outcome. In a 2020 Nature Communications publication, the collaboration identified mechanisms of immune persistence in solid tumor to overcome tumor-immune challenges.